Clinical Trial Update: TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World

View source ↗

Summary

TYGRIS Rest of World, a global observational program evaluating the safety of TYSABRI (natalizumab) in multiple sclerosis, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Status: COMPLETED